La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on improving and preserving human life through the development of novel pharmaceutical products. Riquent®, the company’s leading product in development, treats lupus renal disease, a leading cause of sickness and death in patients with lupus, by preventing or delaying renal flares. Additionally, La Jolla has developed small molecules designed to treat other autoimmune and inflammatory conditions. For further information, visit the Company’s web site at www.ljpc.com.
- 18 years ago
QualityStocks
La Jolla Pharmaceutical Company (NASDAQ: LJPC)
Tags Rodman & Renshaw
Related Post
-
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
In the United States alone, close to one million people are living with MS, with…
-
Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step
California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…
-
Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership
The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…